AF
CRSP icon

Allworth Financial’s CRISPR Therapeutics CRSP Stock Holding History

Allworth Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$550K Sell
10,089
-927
-8% -$48.9K ﹤0.01% 948
2026
Q1 		$524K Buy
11,016
+1,466
+15% +$77.3K ﹤0.01% 936
2025
Q4 		$501K Buy
9,550
+249
+3% +$14.9K ﹤0.01% 935
2025
Q3 		$603K Sell
9,301
-2,056
-18% -$118K ﹤0.01% 825
2025
Q2 		$552K Sell
11,357
-203
-2% -$7.86K ﹤0.01% 808
2025
Q1 		$452K Sell
11,560
-3,518
-23% -$149K ﹤0.01% 709
2024
Q4 		$666K Buy
15,078
+14,398
+2,117% +$680K ﹤0.01% 620
2024
Q3 		$31.9K Sell
680
-1,722
-72% -$87.4K ﹤0.01% 1612
2024
Q2 		$131K Buy
2,402
+1,684
+235% +$97.4K ﹤0.01% 965
2024
Q1 		$48.9K Sell
718
-32
-4% -$2.29K ﹤0.01% 1314
2023
Q4 		$47K Buy
750
+27
+4% +$1.49K ﹤0.01% 1226
2023
Q3 		$32.8K Sell
723
-1
-0.1% -$52 ﹤0.01% 1274
2023
Q2 		$40.6K Buy
724
+2
+0.3% +$113 ﹤0.01% 1190
2023
Q1 		$32.7K Sell
722
-18
-2% -$874 ﹤0.01% 1236
2022
Q4 		$30.1K Sell
740
-3
-0.4% -$159 ﹤0.01% 1201
2022
Q3 		$49K Buy
743
+6
+0.8% +$435 ﹤0.01% 963
2022
Q2 		$45K Buy
737
+128
+21% +$7.53K ﹤0.01% 943
2022
Q1 		$38K Buy
609
+497
+444% +$31.2K ﹤0.01% 989
2021
Q4 		$8K Hold
112
– – ﹤0.01% 1459
2021
Q3 		$13K Buy
112
+32
+40% +$4.02K ﹤0.01% 1171
2021
Q2 		$13K Hold
80
– – ﹤0.01% 962
2021
Q1 		$10K Hold
80
– – ﹤0.01% 978
2020
Q4 		$12K Buy
+80
New +$9.46K ﹤0.01% 785

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allworth Financial's CRSP Position: Q2 2026 in Review

Allworth Financial reduced its CRISPR Therapeutics (CRSP) stake by 8.4% in Q2 2026, selling an estimated $48.9K and leaving 10,089 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #948.

Allworth Financial first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $666K in Q4 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Allworth Financial held 10,089 shares of CRISPR Therapeutics worth $550K as of Q2 2026.
  • Allworth Financial sold 927 CRISPR Therapeutics shares in Q2 2026, an estimated $48.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #948 holding.
  • Allworth Financial first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Allworth Financial's CRISPR Therapeutics position peaked at $666K in Q4 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.